Ekemini A Ogbu1, Shanmuganathan Chandrakasan2, Kelly Rouster-Stevens3, Larry A Greenbaum4, Ignacio Sanz5, Scott E Gillespie6, Chelsea Marion7, Karli Okeson6, Sampath Prahalad3. 1. Department of Pediatrics, Division of Pediatric Allergy, Immunology and Rheumatology, Johns Hopkins University, Baltimore, USA. 2. Department of Pediatrics, Division of Pediatric Hematology/Oncology, Emory University School of Medicine and Children's Healthcare of Atlanta, Georgia, USA. 3. Department of Pediatrics, Division of Pediatric Rheumatology, Emory University School of Medicine and Children's Healthcare of Atlanta, Georgia, USA. 4. Department of Pediatrics, Division of Pediatric Nephrology, Emory University School of Medicine and Children's Healthcare of Atlanta, Georgia, USA. 5. Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Georgia, USA. 6. Department of Pediatrics, Emory University School of Medicine, Georgia, USA. 7. Children's Healthcare of Atlanta, Georgia, USA.
Abstract
OBJECTIVE: To assess whether children with autoimmune cytopenias prior to or at diagnosis of systemic lupus erythematosus (cSLE), differ phenotypically from other cSLE patients; and have a lower risk and severity of lupus nephritis (LN) as observed in prior adult studies. To assess the effect of prior immune therapy for autoimmune cytopenias on 2-year risk of LN. METHODS: This was a retrospective cohort study of incident cSLE cases. We included patients aged less than 17 years at diagnosis. We excluded patients with LN at cSLE diagnosis. Our follow-up period was 2 years. We defined autoimmune cytopenias as either autoimmune hemolytic anemia, immune thrombocytopenia or Evan's syndrome. RESULTS: Forty-three (33%) of the 130 patients had autoimmune cytopenias before or at cSLE diagnosis. Those with autoimmune cytopenias had significantly more neuropsychiatric symptoms and higher mean ESR but less arthritis, malar rash and myositis versus those without autoimmune cytopenias. They had lower 2-year incidence proportion of LN compared to other cSLE patients (7% vs 15%). Of the 16 patients who developed LN, those with autoimmune cytopenias had mostly class V (2 of 3 patients) versus mostly class III and IV in those without autoimmune cytopenias (6 of 12 patients). None of the 13 patients pre-treated for autoimmune cytopenias developed LN. CONCLUSION: Patients with autoimmune cytopenias before or at cSLE diagnosis have intriguing differences from other cSLE patients. They may represent a unique sub-type of cSLE patients and should be further explored.
OBJECTIVE: To assess whether children with autoimmune cytopenias prior to or at diagnosis of systemic lupus erythematosus (cSLE), differ phenotypically from other cSLE patients; and have a lower risk and severity of lupus nephritis (LN) as observed in prior adult studies. To assess the effect of prior immune therapy for autoimmune cytopenias on 2-year risk of LN. METHODS: This was a retrospective cohort study of incident cSLE cases. We included patients aged less than 17 years at diagnosis. We excluded patients with LN at cSLE diagnosis. Our follow-up period was 2 years. We defined autoimmune cytopenias as either autoimmune hemolytic anemia, immune thrombocytopenia or Evan's syndrome. RESULTS: Forty-three (33%) of the 130 patients had autoimmune cytopenias before or at cSLE diagnosis. Those with autoimmune cytopenias had significantly more neuropsychiatric symptoms and higher mean ESR but less arthritis, malar rash and myositis versus those without autoimmune cytopenias. They had lower 2-year incidence proportion of LN compared to other cSLE patients (7% vs 15%). Of the 16 patients who developed LN, those with autoimmune cytopenias had mostly class V (2 of 3 patients) versus mostly class III and IV in those without autoimmune cytopenias (6 of 12 patients). None of the 13 patients pre-treated for autoimmune cytopenias developed LN. CONCLUSION:Patients with autoimmune cytopenias before or at cSLE diagnosis have intriguing differences from other cSLE patients. They may represent a unique sub-type of cSLE patients and should be further explored.
Authors: B Bader-Meunier; J B Armengaud; E Haddad; R Salomon; G Deschênes; I Koné-Paut; T Leblanc; C Loirat; P Niaudet; J C Piette; A M Prieur; P Quartier; F Bouissou; M Foulard; G Leverger; I Lemelle; P Pilet; M Rodière; N Sirvent; P Cochat Journal: J Pediatr Date: 2005-05 Impact factor: 4.406
Authors: T Tarr; B Dérfalvi; N Győri; A Szántó; Z Siminszky; A Malik; A J Szabó; G Szegedi; M Zeher Journal: Lupus Date: 2014-12-15 Impact factor: 2.911
Authors: Monika Katyal; S C Tiwari; Ashok Kumar; A K Dinda; Vaishali Arora; Rajiv Kumar; Nibhriti Das Journal: Mol Immunol Date: 2004-04 Impact factor: 4.407
Authors: N W S Gormezano; D Kern; O L Pereira; G C X Esteves; A M E Sallum; N E Aikawa; R M R Pereira; C A Silva; E Bonfá Journal: Lupus Date: 2016-11-12 Impact factor: 2.911